Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of a Biologics License Application...
Ophthalmology
Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases
Insilico Medicine (HKG: 3696) announced the nomination of ISM9077, an AI-powered, potential first-in-class Target Y...
Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced that the Investigational New Drug (IND) application...
Roche’s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China’s National Medical Products Administration (NMPA)...
Roche’s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for...
China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products...
Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar
Zhaoke Ophthalmology Limited (HKG: 6622) announced the acquisition of global ownership of all intellectual property,...
Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced positive results from its Phase 2 clinical...
Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Changchun High & New Technology Industry (Group) Inc. (SHE: 000661) announced that China’s National Medical...
Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal
Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea’s Samil Pharmaceuticals, Co.,...
Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
Ocumension Therapeutics (HKG: 1477) announced that China’s National Medical Products Administration (NMPA) has approved the...
Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug...
Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant
Bayer AG (ETR: BAYN) announced the completion of its acquisition of Perfuse Therapeutics, Inc., securing...
Shanghai Henlius Biotech’s HLX04-O Meets Primary Endpoints in Phase III Trial for Wet AMD, Demonstrating Non-Inferiority to Ranibizumab
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Phase III international multicenter clinical study...
Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution
Johnson & Johnson (J&J, NYSE: JNJ) announced a $1+ billion investment in Jacksonville, Florida, to...
Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism
Everest Medicines (HKG: 1952) announced a strategic licensing agreement with domestic peer Corxel Pharmaceuticals Limited...
Teva Launches Ahzantive Biosimilar to Bayer’s Eylea Across Europe – Expanding Access to Retinal Disease Treatments
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version...
Cloudbreak Pharma Submits FDA IND for CBT-358, Novel SFA+ Technology-Based Dry Eye Treatment
Cloudbreak Pharma Inc. (HKG: 2592) announced it has submitted an Investigational New Drug (IND) application...
Zhejiang Shapuaisi Acquires Myopia Treatment Technology from Wenzhou Medical University Eye Hospital for $10 Million Plus Royalties
Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (SHA: 603168) announced it has entered into a comprehensive technology...
Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive...